NYMOX Provides Current Update
October 11 2021 - 10:30AM
Nymox Pharmaceutical Corporation (NASDAQ: NYMX) (the “Company”) is
pleased to report today a one-month update to shareholders as a
follow-up to the September communication. The Company reinforces
that its completion tasks for the important Fexapotide
filing have advanced as anticipated and that substantial progress
has ensued.
Company CEO Paul Averback stated, "We are
happy to follow-up today and tell our shareholders that the
main delayed vendor documentation that was incomplete has been
accomplished. We are now certain to have our full documentation for
those materials completed. There remain some standard quality
control steps that are typically involved. Our next follow-up is
expected to provide a more exact forward date for filing as
soon as it is in our hands very soon in this quarter. We
emphasize again that it is fully in the best interests of our
shareholders that management concerns itself with required
quality regulations and stays focused on doing things properly,
regardless of the recent very minor adjustments to the timeline,
which are beyond our control."
The Company also announced today that it will be
participating in several investor conferences and meetings in the
upcoming months.
About Nymox Pharmaceutical Corporation
Nymox Pharmaceutical Corporation specializes in
the research and development of therapeutics and diagnostics, with
a particular emphasis on products targeted for the unmet needs of
the rapidly aging male population in developed economies. The
Company’s lead drug candidate for benign prostatic hyperplasia
(BPH), Fexapotide Triflutate (FT), has completed Phase 3
development in more than 70 clinical centers in the United States,
involving more than 1700 patients during the entire clinical
development program. Currently, the Company will soon be filing for
approval in major economies around the world, including the United
States and Europe.
For more information please
contact info@nymox.com or 800-936-9669.
Forward Looking Statements
To the extent that statements contained in this
press release are not descriptions of historical facts regarding
Nymox, they are forward-looking statements reflecting the current
beliefs and expectations of management made pursuant to the safe
harbor provisions of the Private Securities Litigation Reform Act
of 1995, including statements regarding the need for new options to
treat BPH and prostate cancer, the potential of Fexapotide to treat
BPH and prostate cancer and the estimated timing of further
developments for Fexapotide. Such forward-looking statements
involve substantial risks and uncertainties that could cause our
clinical development program, future results, performance or
achievements to differ significantly from those expressed or
implied by the forward-looking statements. Such risks and
uncertainties include, among others, the uncertainties inherent in
the clinical drug development process, including the regulatory
approval process, the timing of Nymox's regulatory filings, Nymox's
substantial dependence on Fexapotide, Nymox's commercialization
plans and efforts and other matters that could affect the
availability or commercial potential of Fexapotide. Nymox
undertakes no obligation to update or revise any forward looking
statements. For a further description of the risks and
uncertainties that could cause actual results to differ from those
expressed in these forward-looking statements, as well as risks
relating to the business of Nymox in general, see Nymox's current
and future reports filed with the U.S. Securities and Exchange
Commission, including its Annual Report on Form 20-F for the year
ended December 31, 2018, and its Quarterly Reports.
For Further Information
Contact:Randall
Lanham Nymox
Pharmaceutical Corporation1-800-93NYMOXwww.nymox.com
Nymox Pharmaceutical (NASDAQ:NYMX)
Historical Stock Chart
From Mar 2024 to Apr 2024
Nymox Pharmaceutical (NASDAQ:NYMX)
Historical Stock Chart
From Apr 2023 to Apr 2024